SEPTIN9 and colorectal carcinoma: Our team previously has developed a cell-free DNA (cfDNA) test, ColoDefense1.0, that detected methylated SEPT9 and SDC2 simultaneously in a multiplex qPCR assay, exhibiting outstanding sensitivities of 92.3% for all stage CRC and 66.7% for AA with a specificity of 93.2% in stool samples, and sensitivities of 88.9% for CRC and 47.8% for AA with a specificity of 92.8% in plasma samples [8, 9].